Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Antidepressant or Prodrug or Stimulant

Use the filters below to narrow your results.

generic:
brand:
None (43) · (multiple, generic dominant) (1) · Anafranil (1) · Aurorix (1) · Benzedrex (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Edronax (1) · Fetzima (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Norpramin (1) · Parnate (1) · Savella (1) · Serzone (1) · Stablon (1) · Surmontil (1) · Tofranil (1) · Valdoxan (1) · Vivactil (1) · Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
Monoamine releasing agent (8) · Dopamine/norepinephrine reuptake inhibitor (5) · Selective norepinephrine reuptake inhibitor (4) · Irreversible non-selective MAO inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · Norepinephrine–dopamine reuptake inhibitor (2) · Serotonin–norepinephrine reuptake inhibitor (2)
uses:
None (61) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Mild to moderate pain; cough suppression (low-dose). (1)
starting dose:
None (61) · 25 mg (1) · Adult: 15–60 mg every 4 hours as needed. (1)
preparations:
None (61) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
None (61) · 200 mg/d (1) · 360 mg/day (1)
routes:
None (60) · Oral (2) · PO (only formulation marketed in the US). (1)
onset:
None (60) · 30–60 min (PO) (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)
duration:
None (60) · 4–6 hours (1) · Chronic daily dosing (1) · Long (1)
halflife:
None (60) · 2.5–3 hours (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)
bioavailability:
None (60) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · ~50% (highly variable) (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)
pregnancy:
None (60) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1)
legal:
None (60) · Rx-only (1) · Rx-only in US (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)

Showing below up to 63 results in range #1 to #63.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"